Company profile
Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AGLATIMAGENE BESADENOVEC | phase3 | — | 11 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07332000 | phase2 | recruiting | 2025-10-30 | 2026-08-01 | Candel Therapeutics, Inc. | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec |
| NCT00634231 | phase1 | completed | 2010-10-01 | 2015-12-01 | Candel Therapeutics, Inc. | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors |
| NCT00638612 | phase1 | completed | 2008-08-01 | 2013-05-01 | Candel Therapeutics, Inc. | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) |
| NCT07660094 | phase3 | recruiting | 2026-06-15 | 2031-10-22 | Candel Therapeutics, Inc. | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) |
| NCT04495153 | phase2 | active_not_recruiting | 2020-10-13 | 2024-12-31 | Candel Therapeutics, Inc. | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC |
FDA applications (0)
No records yet.